Cutting Rx Opioid Supply Is Not Stopping Diversion — Pain News Network – by Roger Crhiss – Oct 2018
Drug diversion is an increasingly important factor in the opioid overdose crisis.
A new report from Protenus found that 18.7 million pills, valued at around $164 million, were lost due to drug diversion in the United States during the first half of 2018. This represents a vast increase over 2017, when 20.9 million pills were diverted during the entire year.
I’ve posted before about my suspicions that it’s large scale diversion in the supply chain that’s feeding the availability of prescription opioids on the black market, not pain patient prescriptions. These huge numbers of diverted pills make clear that these diverted prescription opioids are not from grandma’s medicine cabinet, but these events don’t “make the news”. Continue reading
Lessons from ‘Prescription Drug Diversion and Pain’ — Pain News Network – September 28, 2018 – By Roger Chris
The new book“Prescription Drug Diversion and Pain” is a textbook treatment of pain management and drug policy amid the opioid crisis.
Written and edited by experts, the book is a scholarly, rigorous and evenhanded examination of the benefits and burdens of opioid pain medication.
Each chapter is written by specialists who address a particular aspect of the opioid crisis, with extensive footnotes justifying every statistic and claim. Much of that data, however, is admittedly flawed.
Diversion of Blame and the Opioid Crisis – By Richard Dobson, MD – Pain News Network – Sept 2018
Dr. Dobson proposes an interesting model of how blame for the “opioid crisis” has fallen on pain patients instead of the drug abusers and drug dealers that are responsible for it.
…after years of bewilderment, I have come upon a clinical description that seems to describe the plight of people who suffer from chronic pain. Let me try to simplify this complicated and mystifying condition.
First, a brief overview of the current situation.
There are five basic groups of people involved in the opioid crisis: Continue reading
DEA Revises Opioid-Quota Rules, Leaving Out Requested Change by Kerry Dooley Young – July 13, 2018
The Drug Enforcement Administration (DEA) will update its established procedures for setting production quotas for addictive drugs without heeding a recommendation from medical groups regarding shortages of injectable opioids.
The DEA on July 11 announced its final decision on changes to its regulations regarding aggregate production quotas (APQs), which it said were initially issued in 1971.
When a policy is close to 50 years old, it shouldn’t be revised or changed as much as thrown out entirely. So much more is known about medications and drugs in general than 50 years ago, it’s ludicrous that such old policies are still used at all. Continue reading
U.S. fines CVS for failing to report opioid theft in New York – June 28, 2018 – Jonathan Stempel
CVS Health Corp agreed to pay a $1.5 million civil fine to resolve U.S. charges that some of its pharmacies in Nassau and Suffolk counties in New York failed to report in a timely manner the loss or theft of prescription drugs, including the opioid hydrocodone.
This is where the real diversion is coming from: the supply chain. Massive quantities of opioid tablets are embezzled, stolen, or “lost” as the pills are transported from the manufacturer to their warehouses, to various other warehouses, and finally to pharmacies. Continue reading
Limiting Opioid Prescribing: The Fallout From Rules Telling Doctors How to Prescribe – Kenneth W. Lin, MD, MPH – May 08, 2018
Hello, everyone. I’m Dr Kenny Lin, a family physician at Georgetown University Medical Center in Washington, DC, and I blog at Common Sense Family Doctor.
The 2016 guideline on prescribing opioids for chronic non-cancer pain from the Centers for Disease Control and Prevention (CDC), which I discussed in a previous Medscape commentary, recommends that clinicians “should avoid increasing dosage to greater than or equal to 90 morphine milligram equivalents (MME) per day or carefully justify a decision to titrate dosage” to that level. Continue reading
DEA plan to stem supply of prescription drugs draws skepticism April 2018 – By Lev Facher @levfacher
Here is another article in support of yesterday’s post: DEA Draws Firestorm of Criticism for New Quotas
With pressure building on the the Drug Enforcement Administration to stem the supply of prescription drugs, a new proposal aims to empower the agency to more aggressively limit manufacturing levels and to put hundreds of drug makers on notice. It’s not yet clear whether the proposal will achieve either goal.
This is a policy that’s completely out of step with reality – overdoses moved on from prescription opioids to illicit opioids (often laced with fentanyl). Continue reading
Suspected drug thefts persist at VA centers | WISH-TV – Hope Yen, AP – May 2017
Federal authorities are investigating dozens of new cases of possible opioid and other drug theft by employees at Veterans Affairs hospitals, a sign the problem isn’t going away as more prescriptions disappear.
Data obtained by The Associated Press show 36 criminal investigations opened by the VA inspector general’s office from Oct. 1 through May 19. It brings the total number of open criminal cases to 108 involving theft or unauthorized drug use
The numbers are an increase from a similar period in the previous year. Continue reading
Are Abuse-Deterrent Opioid Products A Double-Edged Sword? – Practical Pain Management – May 16, 2017 – By Jasmine Shah, PharmD and Ryan W Rodriguez, PharmD, BCPS
Solving the opioid epidemic is complex because of the multifactorial underlying causes. Complicating this issue is the need to maintain access to opioids for patients with chronic pain conditions for which prescription opioid analgesics are the only effective treatment.
Any attempts to mitigate opioid abuse must not have the unintended consequence of eliminating a viable treatment option for patients using opioid medications appropriately and experiencing meaningful clinical improvement. Continue reading
Lyrica and Neurontin Linked to Opioid Overdoses — Pain News Network – May 2017
“It is important that doctors and people dependent on opioids are aware that the number of overdose deaths involving the combination of opioids with gabapentin or pregabalin has increased substantially and that there is evidence now that their concomitant use – either through co-prescription or diversion of prescriptions – increases the risk of acute overdose deaths,” said Matthew Hickman, a Professor of Public Health and Epidemiology
The idea that Lyrica and Neurontin are being abused may be surprising to many patients and doctors, but the drugs are increasingly being used by addicts. Continue reading